Does adding noradrenaline reuptake inhibition to selective serotonin reuptake inhibition improve efficacy in patients with depression? A systematic review of meta-analyses and large randomised pragmatic trials

Journal of Psychopharmacology

Volumn 27, Issue 8, 2013, Pages 740-758

  Bradley, Andrew J ^a   Lenox Smith, Alan J ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

depression; efficacy; noradrenaline; Selective serotonin reuptake inhibitor; serotonin; serotonin noradrenaline reuptake inhibitor

Indexed keywords

CITALOPRAM; DESVENLAFAXINE; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; MILNACIPRAN; PAROXETINE; PLACEBO; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; VENLAFAXINE;

DEPRESSION; DOSE RESPONSE; DRUG DOSE TITRATION; DRUG EFFICACY; HUMAN; META ANALYSIS (TOPIC); MONOTHERAPY; OUTCOME ASSESSMENT; PATIENT CARE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; REVIEW; SYSTEMATIC REVIEW;

DEPRESSION; EFFICACY; NORADRENALINE; SELECTIVE SEROTONIN REUPTAKE INHIBITOR; SEROTONIN; SEROTONIN NORADRENALINE REUPTAKE INHIBITOR;

ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER; HUMANS; NOREPINEPHRINE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEROTONIN; SEROTONIN UPTAKE INHIBITORS;

EID: 84880454038     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881113494937     Document Type: Review

References (91)

1. Allard P, Gram L, Timdahl K, et al. Efficacy and tolerability of venlafaxine in geriatric outpatients with major depression: A double-blind, randomised 6-month comparative trial with citalopram. Int J Geriatr Psychiatry. 2004 ; 19: 1123-1130
2. Diagnostic and Statistical Manual of Mental Disorders Fourth Edition (DSM-IV). Washington, DC: American Psychiatric Association ; 1994:
3. Diagnostic and Statistical Manual of Mental Disorders Fourth Edition., Text Revision (DSM-IV-TR). Washington, DC: American Psychiatric Association ; 2000:
4. Baldomero EB, Ubago JG, Cercos CL, et al. Venlafaxine extended release versus conventional antidepressants in the remission of depressive disorders after previous antidepressant failure: ARGOS study. Depress Anxiety. 2005 ; 22: 68-76
5. Ballesteros J, Callado LF, Gutierrez M. An independent meta-analysis using summary data for clinical response, remission, and discontinuation for any reason from the 6 pivotal phase III randomized clinical trials of duloxetine in major depressive disorder. J Clin Psychopharmacol. 2007 ; 27: 219-221
6. Bauer M, Tharmanathan P, Volz HP, et al. The effect of venlafaxine compared with other antidepressants and placebo in the treatment of major depression: A meta-analysis. Eur Arch Psychiatry Clin Neurosci. 2009 ; 259: 172-185
7. Bielski RJ, Ventura D, Chang CC. A double-blind comparison of escitalopram and venlafaxine extended release in the treatment of major depressive disorder. J Clin Psychiatry. 2004 ; 65: 1190-1196
8. Blier P, Saint-Andre E, Hebert C, et al. Effects of different doses of venlafaxine on serotonin and norepinephrine reuptake in healthy volunteers. Int J Neuropsychopharmacol. 2007 ; 10: 41-50
9. Chen F, Larsen MB, Sanchez C, et al. The S-enantiomer of R,S-citalopram, increases inhibitor binding to the human serotonin transporter by an allosteric mechanism. Comparison with other serotonin transporter inhibitors. Eur Neuropsychopharmacol. 2005 ; 15: 193-198
10. Chen X, Huang X, Hu Y. Efficacy and safety of Duloxetine versus paroxetine for adults' depression: A meta-analysis. Chinese Journal of Evidence-Based Medicine. 2012 ; 12: 320-325
11. Chen ZM, Zhang JH, Li ZW, et al. Venlafaxine versus imipramine,sertraline in treating depression. Chinese Journal of New Drugs and Clinical Remedies. 2001 ; 20: 109-111
12. Cipriani A, Brambilla P, Furukawa T, et al. Fluoxetine versus other types of pharmacotherapy for depression. Cochrane Database Syst Rev. 2005 ;: CD004185
13. Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 12 newgeneration antidepressants: A multiple-treatments meta-analysis. Lancet. 2009a ; 373: 746-758
14. Cipriani A, Koesters M, Furukawa TA, et al. Duloxetine versus other anti-depressive agents for depression. Cochrane Database Syst Rev. 2012a ; 10: CD006533
15. Cipriani A, La Ferla T, Furukawa TA, et al. Sertraline versus other antidepressive agents for depression. Cochrane Database Syst Rev. 2010 ;: D006117
16. Cipriani A, Purgato M, Furukawa TA, et al. Citalopram versus other anti-depressive agents for depression. Cochrane Database Syst Rev 7. 2012b ;: CD006534
17. Cipriani A, Santilli C, Furukawa TA, et al. Escitalopram versus other antidepressive agents for depression. Cochrane Database Syst Rev. 2009b ; 2: CD006532
18. Cook RJ, Sackett DL. The number needed to treat: A clinically useful measure of treatment effect. Brit Med J. 1995 ; 310: 452-454
19. Citalopram: Clinical effect profile in comparison with clomipramine. A controlled multicenter study. Psychopharmacology (Berl). 1986 ; 90: 131-138
20. Paroxetine: A selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study. J Affect Disord. 1990 ; 18: 289-299
21. De Silva VA, Hanwella R. Efficacy and tolerability of venlafaxine versus specific serotonin reuptake inhibitors in treatment of major depressive disorder: A meta-analysis of published studies. Int Clin Psychopharmacol. 2012 ; 27: 8-16
22. Debonnel G, Saint-Andre E, Hebert C, et al. Differential physiological effects of a low dose and high doses of venlafaxine in major depression. Int J Neuropsychopharmacol. 2007 ; 10: 51-61
23. Deecher DC, Beyer CE, Johnston G, et al. Desvenlafaxine succinate: A new serotonin and norepinephrine reuptake inhibitor. J Pharmacol Exp Ther. 2006 ; 318: 657-665
24. Duloxetine Summary of Product Characterisitics, Eli Lilly and Company Limited. Available at: http://www.medicines.org.uk/emc/medicine/15694/SPC/ (accessed 15 June 2013).
25. Eckert L, Lancon C. Duloxetine compared with fluoxetine and venlafaxine: Use of meta-regression analysis for indirect comparisons. BMC Psychiatry. 2006 ; 6: 30
26. Einarson TR, Addis A, Mittmann N, et al. Meta-analysis of venlafaxine, SSRIs and TCAs in the treatment of major depressive disorder. Can J Clin Pharmacol. 1998 ; 5: 205-216
27. Einarson TR, Arikian SR, Casciano J, et al. Comparison of extended-release venlafaxine, serotonin reuptake inhibitors, and tricyclic antidepressants in the treatment of depression: A meta-analysis of randomized controlled trials. Clin Ther. 1999 ; 21: 296-308
28. Entsuah AR, Huang H, Thase ME. Response and remission rates in different subpopulations with major depressive disorder administered venlafaxine, selective serotonin reuptake inhibitors, or placebo. J Clin Psychiatry. 2001 ; 62: 869-877
29. Gartlehner G, Gaynes BN, Hansen RA, et al. Comparative benefits and harms of second-generation antidepressants: Background paper for the American College of Physicians. Ann Intern Med. 2008a ; 149: 734-750
30. Gartlehner G, Hansen RA, Morgan LC, et al. Comparative benefits and harms of second-generation antidepressants for treating major depressive disorder: an updated meta-analysis. Ann Intern Med. 2011 ; 155: 772-785
31. Gartlehner G, Thieda P, Hansen RA, et al. Comparative risk for harms of second-generation antidepressants: A systematic review and meta-analysis. Drug Saf. 2008b ; 31: 851-865
32. Gartlehner G, Thaler K, Hansen RA, et al. The general and comparative efficacy and safety of duloxetine in major depressive disorder: a systematic review and meta-analysis. Drug Saf. 2009 ; 32: 1159-1173
33. Girardi P, Pompili M, Innamorati M, et al. Duloxetine in acute major depression: Review of comparisons to placebo and standard antidepressants using dissimilar methods. Hum Psychopharmacol. 2009 ; 24: 177-190
34. Hansen RA, Gartlehner G, Lohr KN, et al. Efficacy and safety of second-generation antidepressants in the treatment of major depressive disorder. Ann Intern Med. 2005 ; 143: 415-426
35. HigginsJPTGreenS (eds) (2011) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration. Available at: www.cochrane-handbook.org.
36. Isacsson G, Adler M. Randomized clinical trials underestimate the efficacy of antidepressants in less severe depression. Acta Psychiatr Scand. 2012 ; 125: 453-459
37. Kasper S, Spadone C, Verpillat P, et al. Onset of action of escitalopram compared with other antidepressants: Results of a pooled analysis. Int Clin Psychopharmacol. 2006 ; 21: 105-110
38. Katzman MA, Tricco AC, McIntosh D, et al. Paroxetine versus placebo and other agents for depressive disorders: a systematic review and meta-analysis. J Clin Psychiatry. 2007 ; 68: 1845-1859
39. Kennedy SH, Andersen HF, Lam RW. Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysis. J Psychiatry Neurosci. 2006 ; 31: 122-131
40. Kennedy SH, Andersen HF, Thase ME. Escitalopram in the treatment of major depressive disorder: A meta-analysis. Curr Med Res Opin. 2009 ; 25: 161-175
41. Khan A, Bose A, Alexopoulos GS, et al. Double-blind comparison of escitalopram and duloxetine in the acute treatment of major depressive disorder. Clin Drug Investig. 2007 ; 27: 481-492
42. Khan A, Khan SR, Walens G, et al. Frequency of positive studies among fixed and flexible dose antidepressant clinical trials: An analysis of the Food and Drug Administration summary basis of approval reports. Neuropsychopharmacology. 2003 ; 28: 552-557
43. Khan A, Leventhal RM, Khan SR, et al. Severity of depression and response to antidepressants and placebo: An analysis of the Food and Drug Administration database. J Clin Psychopharmacol. 2002 ; 22: 40-45
44. Kobak KA, Taylor LH, Dottl SL, et al. A computer-administered telephone interview to identify mental disorders. JAMA. 1997 ; 278: 905-910
45. Koesters M, Zhang Y, Ma YC, et al. What can we learn from Chinese randomized controlled trials? A systematic review and meta-analysis of Chinese venlafaxine studies. J Clin Psychopharmacol. 2011 ; 31: 194-200
46. Kornstein SG, Li D, Mao Y, et al. Escitalopram versus SNRI antidepressants in the acute treatment of major depressive disorder: Integrative analysis of four double-blind, randomized clinical trials. CNS Spectr. 2009 ; 14: 326-333
47. Lam RW, Andersen HF, Wade AG. Escitalopram and duloxetine in the treatment of major depressive disorder: A pooled analysis of two trials. Int Clin Psychopharmacol. 2008 ; 23: 181-187
48. Lam RW, Lonn SL, Despiegel N. Escitalopram versus serotonin noradrenaline reuptake inhibitors as second step treatment for patients with major depressive disorder: A pooled analysis. Int Clin Psychopharmacol. 2010 ; 25: 199-203
49. Lane P. Handling drop-out in longitudinal clinical trials: A comparison of the LOCF and MMRM approaches. Pharm Stat. 2008 ; 7: 93-106
50. Lecrubier Y. Clinical utility of venlafaxine in comparison with other antidepressants. Int Clin Psychopharmacol. 1995 ; 10: S29 - S35
51. Lenox-Smith A, Macdonald M, Bradley A, et al. Duloxetine vs individual generic selective serotonin reuptake inhibitors (SSRIs) in the treatment of a severe depressive episode. J Psychopharmacol. 2011 ; 25: A19
52. Lenox-Smith AJ, Jiang Q. Venlafaxine extended release versus citalopram in patients with depression unresponsive to a selective serotonin reuptake inhibitor. Int Clin Psychopharmacol. 2008 ; 23: 113-119
53. Lieberman JA, Greenhouse J, Hamer RM, et al. Comparing the effects of antidepressants: Consensus guidelines for evaluating quantitative reviews of antidepressant efficacy. Neuropsychopharmacology. 2005 ; 30: 445-460
54. Machado M, Einarson TR. Comparison of SSRIs and SNRIs in major depressive disorder: A meta-analysis of head-to-head randomized clinical trials. J Clin Pharm Ther. 2010 ; 35: 177-188
55. Machado M, Iskedjian M, Ruiz I, et al. Remission, dropouts, and adverse drug reaction rates in major depressive disorder: A meta-analysis of head-to-head trials. Curr Med Res Opin. 2006 ; 22: 1825-1837
56. Mallinckrodt CH, Clark WS, David SR. Accounting for dropout bias using mixed-effects models. J Biopharm Stat. 2001 ; 11: 9-21
57. Mallinckrodt CH, Prakash A, Houston JP, et al. Differential antidepressant symptom efficacy: Placebo-controlled comparisons of duloxetine and SSRIs (fluoxetine, paroxetine, escitalopram). Neuropsychobiology. 2007 ; 56: 73-85
58. Martinez JM, Katon W, Greist JH, et al. A pragmatic 12-week, randomized trial of duloxetine versus generic selective serotonin-reuptake inhibitors in the treatment of adult outpatients in a moderate-to-severe depressive episode. Int Clin Psychopharmacol. 2012 ; 27: 17-26
59. Mehtonen OP, Sogaard J, Roponen P, et al. Randomized, double-blind comparison of venlafaxine and sertraline in outpatients with major depressive disorder. Venlafaxine 631 Study Group. J Clin Psychiatry. 2000 ; 61: 95-100
60. Montgomery SA, Huusom AK, Bothmer J. A randomised study comparing escitalopram with venlafaxine XR in primary care patients with major depressive disorder. Neuropsychobiology. 2004 ; 50: 57-64
61. Nakagawa A, Watanabe N, Omori IM, et al. Milnacipran versus other antidepressive agents for depression. Cochrane Database Syst Rev. 2009 ;: CD006529
62. The Treatment and Management of Depression in Adults. National Clinical Guideline 90. London: National Institue for Health and Clinical Excellence ; 2010:
63. Nemeroff CB, Entsuah R, Benattia I, et al. Comprehensive analysis of remission (COMPARE) with venlafaxine versus SSRIs. Biol Psychiatry. 2008 ; 63: 424-434
64. Omori IM, Watanabe N, Nakagawa A, et al. Efficacy, tolerability and side-effect profile of fluvoxamine for major depression: Meta-analysis. J Psychopharmacol. 2009 ; 23: 539-550
65. Omori IM, Watanabe N, Nakagawa A, et al. Fluvoxamine versus other anti-depressive agents for depression. Cochrane Database Syst Rev. 2010 ;: CD006114
66. Oslin DW, Ten Have TR, Streim JE, et al. Probing the safety of medications in the frail elderly: Evidence from a randomized clinical trial of sertraline and venlafaxine in depressed nursing home residents. J Clin Psychiatry. 2003 ; 64: 875-882
67. Papakostas GI, Fava M. A meta-analysis of clinical trials comparing milnacipran, a serotonin - norepinephrine reuptake inhibitor, with a selective serotonin reuptake inhibitor for the treatment of major depressive disorder. Eur Neuropsychopharmacol. 2007 ; 17: 32-36
68. Papakostas GI, Fava M, Thase ME. Treatment of SSRI-resistant depression: A meta-analysis comparing within- versus across-class switches. Biol Psychiatry. 2008 ; 63: 699-704
69. Papakostas GI, Thase ME, Fava M, et al. Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agents. Biol Psychiatry. 2007 ; 62: 1217-1227
70. Paroxetine Summary of Product Characterisitcs GlaxoSmithKline. Available at: http://www.medicines.org.uk/emc/medicine/2057/SPC/ (accessed 15 June 2013).
71. Puech A, Montgomery SA, Prost JF, et al. Milnacipran, a new serotonin and noradrenaline reuptake inhibitor: An overview of its antidepressant activity and clinical tolerability. Int Clin Psychopharmacol. 1997 ; 12: 99-108
72. Puozzo C, Panconi E, Deprez D. Pharmacology and pharmacokinetics of milnacipran. Int Clin Psychopharmacol. 2002 ; 17: S25 - S35
73. Ramsberg J, Asseburg C, Henriksson M. Effectiveness and cost-effectiveness of antidepressants in primary care: a multiple treatment comparison meta-analysis and cost-effectiveness model. PLoS One. 2012 ; 7: e42003
74. Richelson E. Interactions of antidepressants with neurotransmitter transporters and receptors and their clinical relevance. J Clin Psychiatry. 2003 ; 64: S5 - S12
75. Rush AJ, Trivedi MH, Wisniewski SR, et al. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med. 2006 ; 354: 1231-1242
76. Schacht A, Dyachkova Y, Walton RJ. Critical evaluation of mixed treatment comparison meta-analyses using examples assessing antidepressants and opioid detoxification treatments. Int J Methods Psychiatr Res. 2013 ; 22: 166-174
77. Schmitt AB, Bauer M, Volz HP, et al. Differential effects of venlafaxine in the treatment of major depressive disorder according to baseline severity. Eur Arch Psychiatry Clin Neurosci. 2009 ; 259: 329-339
78. Schueler YB, Koesters M, Wieseler B, et al. A systematic review of duloxetine and venlafaxine in major depression, including unpublished data. Acta Psychiatr Scand. 2011 ; 123: 247-265
79. Shelton C, Entsuah R, Padmanabhan SK, et al. Venlafaxine XR demonstrates higher rates of sustained remission compared to fluoxetine, paroxetine or placebo. Int Clin Psychopharmacol. 2005 ; 20: 233-238
80. Siddiqui O, Hung HM, O'Neill R. MMRM vs LOCF: A comprehensive comparison based on simulation study and 25 NDA datasets. J Biopharm Stat. 2009 ; 19: 227-246
81. Sinyor M, Levitt AJ, Cheung AH, et al. Does inclusion of a placebo arm influence response to active antidepressant treatment in randomized controlled trials? Results from pooled and meta-analyses. J Clin Psychiatry. 2010 ; 71: 270-279
82. Smith D, Dempster C, Glanville J, et al. Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: A meta-analysis. Br J Psychiatry. 2002 ; 180: 396-404
83. Stahl SM, Entsuah R, Rudolph RL. Comparative efficacy between venlafaxine and SSRIs: a pooled analysis of patients with depression. Biol Psychiatry. 2002 ; 52: 1166-1174
84. Stahl SM, Grady MM, Moret C, et al. SNRIs: Their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants. CNS Spectr. 2005 ; 10: 732-747
85. Takano A, Halldin C, Farde L. SERT and NET occupancy by venlafaxine and milnacipran in nonhuman primates: A PET study. Psychopharmacology (Berl). 2013 ; 226: 147-153
86. Thase ME, Entsuah AR, Rudolph RL. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry. 2001 ; 178: 234-241
87. Thase ME, Ninan PT, Musgnung JJ, et al. Remission with venlafaxine extended release or selective serotonin reuptake inhibitors in depressed patients: A randomized, open-label study. Prim Care Companion CNS Disord. 2011 ; 13 (1). e1 - e9
88. Thase ME, Pritchett YL, Ossanna MJ, et al. Efficacy of duloxetine and selective serotonin reuptake inhibitors: Comparisons as assessed by remission rates in patients with major depressive disorder. J Clin Psychopharmacol. 2007 ; 27: 672-676
89. Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: Implications for clinical practice. Am J Psychiatry. 2006 ; 163: 28-40
90. Wade A, Gembert K, Florea I. A comparative study of the efficacy of acute and continuation treatment with escitalopram versus duloxetine in patients with major depressive disorder. Curr Med Res Opin. 2007 ; 23: 1605-1614
91. Weinmann S, Becker T, Koesters M. Re-evaluation of the efficacy and tolerability of venlafaxine vs SSRI: meta-analysis. Psychopharmacology (Berl). 2008 ; 196: 511-520